Diabetes unit continues to power growth at Abbott with Lingo coming to U.S. ‘soon’

t:slim X2 Insulin Pump from Tandem Diabetes Care with Abbott’s Freestyle Libre 2 Plus sensor integration now available in the United States. [Image courtesy of Abbott/Tandem Diabetes Care]With continued progress on established platforms, new acquisitions and new products, Abbott (NYSE: ABT) + has high expectations for its Diabetes business.

Speaking at the J.P. Morgan Healthcare Conference, CEO Robert Ford highlighted diabetes as a key area for near-term growth. Specifically, in the presentation transcribed by SeekingAlpha, Ford said he expects the FreeStyle Libre continuous glucose monitor (CGM) to significantly drive growth.

“FreeStyle Libre has fundamentally changed the management of diabetes,” Ford said. “[It’s] our market-leading wearable glucose sensor… There are now more than 5 million users of Libre around the world, with 2 million in the United States.”

Ford said the com…

Read more
  • 0

The biggest stories from the 2024 J.P. Morgan Healthcare Conference

Medtronic’s Geoff Martha, Dexcom’s Kevin Sayer and J&J’s Joaquin Duato spoke at this year’s J.P. Morgan Healthcare Conference.

Some of the biggest names in medtech came together this week at the J.P. Morgan Healthcare Conference. They shared updates on financial progress, operational changes and new products, among other things.

Medtronic shared details on plans to restore earnings power, while Abbott highlighted the success of its FreeStyle Libre system. Shockwave Medical outlined its plans for growth, while Dexom

Here are some of the biggest stories to come out of this year’s edition of the J.P. Morgan Healthcare Conference.

Medtronic focuses on earnings power while shifting operational setup

Medtronic Chair and CEO Geoff Martha’s presentation centered on profits for the medtech giant.

“Our top priority is restoring our earnings power — full stop,” he said. “We continue to be this mission-driven company th…

Read more
  • 0

Shockwave Medical plans for growth with 2-3 product launches each year

The Shockwave C2+ catheter. [Image courtesy of Shockwave Medical]It was a busy 2023 for Shockwave Medical (Nasdaq:SWAV), with product launches, funding rounds and M&A at the heart of it.

The company, which develops intravascular lithotripsy (IVL) technology, first made waves last year with its acquisition of Neovasc. Neovasc develops the Reducer system for addressing refractory angina.

Shockwave remained in the middle of M&A talk, but on the other side of it as the year wore on. First, rumors swirled of Boston Scientific’s interest in acquiring the company. Weeks later, reports of interest from Johnson & Johnson and Medtronic came out as well.

While no deals came to fruition, the heightened interest in the company’s IVL technology remains. Shockwave carried on by raising $650 million in a private offering, then launching the Shockwave C2+ coronary IVL catheter following the receipt of FDA approval.

In a presentation at the J.P…

Read more
  • 0

Medtronic CEO: ‘Our top priority is restoring our earnings power — full stop.’

Medtronic Chair and CEO Geoff Martha [Photo courtesy of Medtronic]Medtronic (NYSE: MDT) + Chair and CEO Geoff Martha focused on the push for profits at the world’s largest medical device manufacturer in his presentation at the J.P. Morgan Healthcare Conference today.

“Our top priority is restoring our earnings power — full stop,” he said, citing Medtronic’s recent reorganizations and changes to incentives, product approvals and launches, and new initiatives like the Medtronic AI Center of Excellence.

“We continue to be this mission-driven company that you know Medtronic to be and our customers and patients know Medtronic to be, but at the same time, performance driven,” he said. “You’ve got to be both. It’s not one without the other: no margin, no mission.”

Martha also offered details of Medtronic’s efforts to leverage its buying power and improve ef…

Read more
  • 0